FTC Clears Cephalon's $225M Gemin X Buyout

Law360, New York (April 5, 2011, 3:53 PM EDT) -- The Federal Trade Commission on Tuesday gave Cephalon Inc. the go-ahead for its $225 million acquisition of Gemin X Pharmaceuticals Inc., a privately held biopharmaceutical company developing cutting-edge cancer therapeutics.

The FTC granted Cephalon early termination of the customary 30-day antitrust review, finding that the deal, which bolsters Cephalon’s oncology portfolio, poses no threat to competition in the emerging market for cancer treatments.

The companies announced the merger on March 21, saying that the $225 million cash transaction should close in the second quarter 2011, at...
To view the full article, register now.